Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising data in early patient assessments . Ongoing https://bookmarksea.com/story21324439/retatrutide-emerging-studies-and-potential-therapeutic-uses